Why did the FDA refuse Moderna's flu application?
What regulators found and what comes next
U.S. regulators told the company they would not accept its application to license an mRNA flu vaccine, and Moderna said the Food and Drug Administration declined to review the submission. The refusal centers on how Moderna designed its pivotal trial: the FDA concluded the company had compared its new mRNA shot against a flu vaccine that was not the best available standard of care. Agency reviewers argued that the comparator used in the trial did not meet expectations for demonstrating that an updated product would be superior or appropriately noninferior to current options.
Company and agency exchanged sharp statements after the decision. Moderna said it was seeking a meeting to discuss the refusal and suggested the action could have broader implications for the regulatory pathway for new and updated influenza vaccines that use mRNA technology. Agency officials and reporting inside the FDA stressed internal disagreement: senior leadership overruled reviewers in a separate report, and the public dispute has prompted other FDA officials to defend the decision.
Why it matters
- The refusal delays potential U.S. access to a new mRNA flu platform that companies argue could be updated faster than conventional vaccines.
- It raises questions about trial design expectations for next-generation vaccines, including what comparator vaccines are acceptable.
- The decision may influence other manufacturers planning similar mRNA respiratory vaccines and could shape FDA guidance on trial standards.
What is still unknown
It’s still unclear whether Moderna will refile with a new comparator or additional data, how long a resubmission would take, or when the FDA might issue formal guidance clarifying acceptable trial designs for updated flu products. The company has requested a meeting with regulators; outcomes from that meeting will determine the next steps and potential timelines for any review.